TEST TO SLASH BREAST CANCER CHEMO

AS MANY as 5,000 British breast cancer patients a year could be spared the ordeal of chemotherapy after one of the biggest breakthroughs in the last two decades.

A landmark study has found that a significant proportion of women with the disease need only a daily pill – such as tamoxifen – to stop their cancer returning after surgery.

Remarkably, the researchers believe that these women can be easily identified via a simple genetic test that is already available on the NHS.

Currently, most breast cancer sufferers undergo a gruelling six-month course of chemotherapy after having either a lumpectomy or mastectomy to remove their tumour.

The chemo is supposed to ensure their cancer doesn’t return, but it can come with debilitating side effects.

However, today’s study says that many of these women would do just as well if they simply took a daily hormone therapy pill instead.

It is based on research involving more than 10,000 women, led by Montefiore Medical Centre in New York, and presented at the largest cancer conference in the world.

Last night, Dr Alistair Ring, a consultant medical oncologist

at the Royal Marsden Hospital in London, described the study as the most significant breast cancer breakthrough in 20 years.

‘It is a significant step because it is about avoiding a treatment that, for most people diagnosed with cancer, is what they all fear being suggested to have,’ he said.

‘our chemotherapy use will drop. as an oncologist, on Monday in the clinic, I will offer less chemotherapy that will not be of benefit to patients and that is very reassuring to know that when I am offering patients chemotherapy, they are likely to benefit from it.’

In Britain, 23,000 women a year are diagnosed with hormone receptor-positive,

‘Life-changing breakthrough’

HeR2-negative, axillary node-negative early-stage breast cancer – the most common type. In total, this type affects half of all breast cancer sufferers.

These women, whose cancer has not yet spread to their lymph nodes, will first have surgery in the form of a lumpectomy or mastectomy to remove the cancer, and may receive radiotherapy.

Then comes hormone therapy pills such as tamoxifen, which block or slow down signals in the body that trigger the growth of cancer cells, and are typically taken for five years.

Patients often also have four to six months of chemotherapy after surgery, to kill any remaining cancer cells.

This is vital for those with the highest risk of their breast cancer returning after surgery, but it comes with side effects such as hair loss, sickness and fatigue.

However, about 69 per cent of women actually fall into a lower risk group, known as ‘intermediate’. For these, the benefits of chemotherapy have always been less clear cut.

Traditionally, it has been up to doctors to decide if they should have the harrowing treatment. The results of today’s study, however, show that these women do not need chemotherapy.

It found that after nine years of taking daily hormone therapy pills, the survival rate for these patients was 93.9 per cent, which is almost exactly the same as the 93.8 per cent rate if women had undergone chemotherapy too.

Figures for those whose cancer returned were also almost identical.

Women in this intermediate group can be accurately identified with a genetic test, known as the oncotype DX test, which detects 21 genes in breast cancer tumours and grades their risk of the disease returning from zero to 100. The Us study found chemotherapy is unnecessary for all intermediate women – those with scores from 11 to 25.

This means 3,000 to 5,000 women in Britain could be spared the treatment every year, according to experts.

The genetic test, which takes two weeks to return results and has been widely available since 2013, costs £2,580, and the NHs gets it for a reduced rate.

Rachel Rawson, clinical nurse specialist at charity Breast Cancer Care, said last night: ‘This life-changing breakthrough is absolutely wonderful news as it could liberate thousands of women from the agony of chemotherapy.

‘every day women with certain types of breast cancer face the terrible dilemma of whether or not to have the treatment, without hard facts about the benefit for them.

‘side effects, such as hair loss, severe pain and infertility, can be utterly devastating and linger long after they walk out the hospital doors.’

Chemotherapy typically costs £4,500 per patient, so the findings could save the health service millions of pounds.

The results were presented during the plenary sessions at the american society of Clinical oncology conference in Chicago, which is for research with the most potential to change patient care.

Lead author Dr Joseph sparano said: ‘our study shows that chemotherapy may be avoided in about 70 per cent of these women when its use is guided by the test, thus limiting chemotherapy to the 30 per cent who we can predict will benefit from it.’